AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$FTRE

Morais Mark A. sold $89K of FTRE

Morais Mark A. (Chief Operating Officer) sold 4,892 shares of Fortrea Holdings Inc. (FTRE) at $18.19 on 2026-08-19.

Original reporting
SEC EDGAR · Morais Mark A.
Published Aug 19, 2026, 10:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 10:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$FTRE
Neutral
high confidence
Mentioned
$FTRE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FTRENeutralLow
01

Why it matters

The disclosed sale is modest and does not provide a clear trading signal.

02

Market read

Limited relevance; the insider sale is small and unlikely to affect market perception.

03

What to watch

The sale was not pre‑arranged; however, the officer retains a sizable position.

Relevance 3/10Novelty 4/10Timing: reported today

Background

Form 4 filings disclose insider transactions; traders monitor them for potential signals.

Company-level read

Ticker impact

$FTRENeutralHigh confidence
Context

COO Mark A. Morais sold 4,892 shares for $88,985, reducing his stake to 77,786 shares.

Expected impact

No significant impact expected.

Evidence & confidence

The transaction size is small relative to market cap and no 10b5-1 plan was used.

Market effects

Sector

None; the sale does not affect the broader sector.

Regional

None; limited to Fortrea shareholders.

Global

None

Counterpoint

What could challenge this read

Even small insider sells can signal concerns, but no pattern suggests material risk.

Key entities

  • Company
    Fortrea Holdings Inc.

    US‑listed specialty chemicals producer.

  • Insider
    Mark A. Morais

    Chief Operating Officer of Fortrea.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FTRE insider trading history →

Related articles

SEP 2
$FTREMed

Fortrea (FTRE) Stock Is Up, What You Need To Know

Fortrea Holdings (FTRE) shares rose 2.8% after acquiring Worldwide Clinical Trials' Early Phase Services division, expanding its clinical research capabilities. The acquisition includes facilities in Texas. Fortrea's stock is volatile, with a 52-week high of $20.70. Q3 revenue was $701.3M, beating estimates, but earnings missed. Full-year revenue guidance was raised to $2.73B.

financialcontent.com2 min
SEP 2
$FTREHigh

Fortrea To Acquire Early Phase Services From Worldwide Clinical Trials; Stock Up

Fortrea Holdings (FTRE) agreed to buy the Early Phase Services division of Worldwide Clinical Trials, including labs and clinical units in Texas. The deal expands Fortrea's early development network, adding bioanalytical and clinical pharmacology capabilities. FTRE shares rose 5.98% to $18.78. According to the company, the acquisition supports growth and increases long-term shareholder value.

rttnews.com2 min
SEP 2
$FTREMed

Fortrea Holdings Inc: Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea (FTRE) will acquire Worldwide Clinical Trials' Early Phase Services division for $45M, including a bioanalytical lab and clinical pharmacology unit. The deal expands Fortrea's early clinical development capabilities, enhancing its platform for Phases I-IV studies. Worldwide will focus on its late-stage business. The transaction is subject to regulatory approvals.

finanznachrichten.de2 min